ADIL: Adial Pharmaceuticals Inc. Price-to-Revenue Coefficient

Brandmark of Adial Pharmaceuticals (ADIL)

Adial Pharmaceuticals (ADIL) delegates its clinical trials for alcoholism treatment to external contractors to optimize expenses. The company operates in a niche sector where it faces pressure from government programs and the risk of expansion by industry behemoths. The current P/S multiple shows that the value of the indicator is , while management strictly adheres to FDA regulations to protect shareholder interests.

Price-to-Revenue Ratio: Adial Pharmaceuticals, Inc. (ADIL) for 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Adial Pharmaceuticals (ADIL)

- stock price and consensus target price:
Share Price adialpharma.com|ADIL - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Adial|ADIL - Enterprise Value
- company book value details:
Book Value per Share Adial Pharmaceuticals|ADIL - Company Book Value|Market Value to Book Value Ratio adialpharma.com|ADIL - Cumulative Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Adial Pharmaceuticals|ADIL - Long-Term Debt to Equity|Current Liabilities to Equity adialpharma.com|ADIL - Company Aggregate Debts|Debt to Net Assets Ratio Adial|ADIL - Company Long-Term Debts|Company Short-Term Debts Adial Pharmaceuticals|Intermediate Coverage Ratio adialpharma.com
- company profitability and valuation multiples indicators:
ADIL - Company Net Income|Future Profit Adial Pharmaceuticals|ADIL - P/E Multiple|Forward P/E Multiple adialpharma.com|ADIL - PEG Multiple|Enterprise Value to EBITDA Ratio Adial|ADIL - Operating profit EBITDA|Net earnings per one share for the last twelve months Adial Pharmaceuticals|ADIL - Net earnings per share for the last 12 months|Quarterly EPS earnings growth adialpharma.com|ADIL - Net earnings per share growth this year|Projected earnings per share increase next year Adial Pharmaceuticals
- total revenue and sales volume data:
ADIL - Revenue and Sales Volume|Company Future Sales adialpharma.com|ADIL - P/S Multiple|Forward Price-to-Revenue Multiple Adial
General company analysis:Adial Pharmaceuticals Inc., ADIL
Finished products of Adial Pharmaceuticals

The P/S multiple compares the market value of a business to its actual revenue, allowing for a real-time assessment of the premium investors are willing to pay for every dollar of sales. By analyzing the P/S multiple trend, one can understand how the automation of drug synthesis and packaging at Adial Pharmaceuticals (ADIL) impacts capitalization, confirming the asset's fundamental stability through increased production efficiency.

Competing companies

indivior.com - Market Cap to Revenue Ratio|P/S Multiple COLL (Collegium Pharmaceutical, Inc.)|Price-to-Revenue Coefficient Cronos Group Inc (CRON)|Tweed - P/S Multiple|HITI - P/S Multiple|auroramj.com (ACB) - Price-to-Revenue Ratio|ACHV (achievelifesciences.com) - Price-to-Revenue Ratio|Market Cap to Revenue SKYE|ANEB: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio InterCure Ltd. (INCR)|NTRB: Price-to-Sales Ratio|P/S Multiple NSRX (Nasus Pharma)|Market Capitalization-to-Revenue Ratio IGC|MIRA Pharma - P/S Multiple|FLGC - P/S Multiple|imcannabis.com (IMCC) - Price-to-Revenue Ratio|Artelo Biosciences, Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Ensysce Biosciences Inc.|Market Cap to Revenue Titan Pharma (TTNP)|P/S Multiple GNLN|P/S Multiple InMed Pharmaceuticals Inc (INM)|P/S Multiple AKAN (Akanda Corporation)|ENVB - Market Cap to Revenue|Bright Green Corp - P/S Multiple|Price to Sales Hempacco Co Inc.